Log in or Sign up for Free to view tailored content for your specialty!
Rheumatoid Arthritis News
FDA approves Amgen’s rituximab biosimilar for treatment of moderate-to-severe RA
The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies.
FDA approves Amgen’s rituximab biosimilar for treatment of moderate-to-severe RA
The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: Implementing a wellness strategy improves signs of IMIDs
CLEVELAND — It is important to implement a wellness strategy for patients who have immune-mediated inflammatory disease, according to M. Elaine Husni, MD, MPH, of the department of rheumatic and immunologic disease at the Cleveland Clinic.
VIDEO: Vaccine discussion important for patients with IMIDs
CLEVELAND — Cassandra Calabrese, DO, emphasized the importance of vaccines for patients with immune-mediated inflammatory diseases at the Medical Dermatology Therapy Update II meeting.
‘More than half’ of rheumatology patients reported post-traumatic stress during COVID-19
More than half of a cohort of patients with rheumatic or musculoskeletal diseases reported experiencing some post-traumatic stress outcomes during the COVID-19 pandemic, according to data presented at the EULAR 2022 Congress.
Selexipag improves outcomes in PAH-associated connective tissue disease in real-world study
SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.
Patients with depression demonstrate six-fold increased mortality risk in RA
Depression is associated with a six-fold increased risk for mortality in patients with incident rheumatoid arthritis, according to data presented at the EULAR 2022 Congress.
COVID-19 mRNA vaccines ‘highly effective’ in immune-mediated inflammatory disease
A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.
VIDEO: Switching drug class can result in ‘home run’ response in rheumatoid arthritis
DESTIN, Fla. — Switching to a different drug class with a different mechanism of action can improve response in patients with difficult-to-treat rheumatoid arthritis, according to Janet Pope, MD, of Western University, in Ontario, Canada.
EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs
Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read